NCT07319897 2026-01-06
A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.
Peking University First Hospital
Phase 2/3 Not yet recruiting
Clinical Trials
13 trialsNCT07075185 2025-09-02
inMMyCAR
Kelonia Therapeutics, Inc.
Phase 1 Recruiting
NCT03896737 2025-08-11
Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara
European Myeloma Network B.V.
Phase 2 Active not recruiting
NCT06028087 2025-03-14
Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment
Gruppo Italiano Malattie EMatologiche dell'Adulto
Recruiting
NCT01093196 2024-11-07
Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT05641324 2024-02-12
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
Anaveon AG
Phase 1 Terminated
NCT01190787 2024-01-23
Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone
European Myeloma Network B.V.
Phase 2 Completed
NCT02204241 2023-07-03
CCD
European Myeloma Network B.V.
Phase 1/2 Completed
NCT01160107 2023-06-29
RP_MPR
Fondazione EMN Italy Onlus
Phase 2 Completed
NCT04338386 2020-04-10
Detection and Pathogenesis of Novel Protein F
Wuhan Asia Heart Hospital
Not yet recruiting
NCT02189343 2019-11-21
Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Celgene
Phase 1 Completed
NCT00232934 2018-08-02
Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients
Gruppo Italiano per lo Studio del Mieloma Multiplo
Phase 3 Completed
NCT00639054 2016-01-07
MM-FISH/DNA
Rigshospitalet, Denmark
Completed